Biotech

All Articles

A deeper examine Ferocious Biotech's Fierce 15

.In this week's episode of "The Leading Line," our company are actually diving in to Tough Biotech's...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration celebrating the approval of Alzhei...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings ...

Lykos will inquire FDA to reevaluate its choice complying with denial of MDMA therapy for trauma

.Following an unsatisfactory presenting for Lykos Therapeutics' MDMA prospect for post-traumatic str...

AN 2 one-halfs roll call, stops period 3 trial after records disappoint

.AN2 Therapies is reviewing its own business in feedback to uninspired midphase records, pledging to...

Merck pays for $700M for bispecific, spying autoimmune opening as well as opportunity to test Amgen in cancer

.Merck &amp Co. is actually paying out $700 thousand in advance to test Amgen in a blood cancer cell...

Gilead pays J&ampJ $320M to exit licensing deal for seladelpar

.Along With Gilead Sciences about to an FDA selection for its liver illness medicine seladelpar, the...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily find the providers establishing tents at basecamp behind Eli Lilly in an...

Entero giving up team, moving out of workplace and stopping briefly R&ampD

.Bed mattress Liquidators has transformed Entero Therapeutics white as a slab. The lender purchased ...

Exelixis loses ADC after determining it is actually no match for Tivdak

.Exelixis is actually surrendering on its tissue element (TF)- targeting antibody-drug conjugate aft...